{"data":[{"accessionNo":"0000919574-26-005202","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Sirenia Capital Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":5963936,"percentOfClass":9.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-005202","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Alex Silverstein","reportingCik":null,"personType":"HC,IN","sharesOwned":5963936,"percentOfClass":9.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-005487","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2366453,"percentOfClass":3.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-005487","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":2366453,"percentOfClass":3.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-005487","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":2366453,"percentOfClass":3.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-003921","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-08","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":3197764,"percentOfClass":5.1,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-003921","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-08","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":3197764,"percentOfClass":5.1,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-003921","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-08","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3197764,"percentOfClass":5.1,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-003492","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":2722754,"percentOfClass":4.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-003492","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":2722754,"percentOfClass":4.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000919574-26-003492","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":"25056L103","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2722754,"percentOfClass":4.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0001072613-26-000257","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-09","reportingPerson":"Simeon George","reportingCik":null,"personType":"IN","sharesOwned":6607892,"percentOfClass":10.7,"filedAt":"2026-03-11","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0001072613-26-000257","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-09","reportingPerson":"SR One Capital Management, LLC","reportingCik":null,"personType":"HC","sharesOwned":6526476,"percentOfClass":10.6,"filedAt":"2026-03-11","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0001072613-26-000257","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-09","reportingPerson":"SR One Capital Fund I Aggregator, LP","reportingCik":"0001848319","personType":"PN","sharesOwned":6526476,"percentOfClass":10.6,"filedAt":"2026-03-11","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0001072613-26-000257","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-09","reportingPerson":"SR One Capital Partners I, LP","reportingCik":null,"personType":"PN","sharesOwned":6526476,"percentOfClass":10.6,"filedAt":"2026-03-11","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000902664-26-001131","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5372004,"percentOfClass":9.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000902664-26-001131","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":5372004,"percentOfClass":9.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000902664-26-001131","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":5372004,"percentOfClass":9.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000710","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-14","reportingPerson":"Logos Global Management LP","reportingCik":"0001792126","personType":"IA,PN","sharesOwned":2500000,"percentOfClass":4.4,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000710","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-14","reportingPerson":"Arsani William","reportingCik":"0001848372","personType":"IN,HC","sharesOwned":2515000,"percentOfClass":4.4,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000710","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-14","reportingPerson":"Logos Global Management GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":2500000,"percentOfClass":4.4,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000710","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-14","reportingPerson":"Logos Global Master Fund LP","reportingCik":"0001831371","personType":"PN","sharesOwned":1500000,"percentOfClass":2.6,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000710","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-14","reportingPerson":"Logos GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":1500000,"percentOfClass":2.6,"filedAt":"2025-11-18","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000657","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-07","reportingPerson":"Logos Global Management LP","reportingCik":"0001792126","personType":"IA,PN","sharesOwned":3240000,"percentOfClass":5.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000657","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-07","reportingPerson":"Logos Global Management GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":3240000,"percentOfClass":5.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000657","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-07","reportingPerson":"Arsani William","reportingCik":"0001848372","personType":"IN,HC","sharesOwned":3255000,"percentOfClass":5.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000657","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-07","reportingPerson":"Logos Global Master Fund LP","reportingCik":"0001831371","personType":"PN","sharesOwned":2240000,"percentOfClass":3.9,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"},{"accessionNo":"0000935836-25-000657","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001807120","issuerName":"Design Therapeutics, Inc.","ticker":"DSGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-07","reportingPerson":"Logos GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":2240000,"percentOfClass":3.9,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn"}],"updatedAt":"2026-11-04T04:22:26.096Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/dsgn","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}